论文信息 - Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC). - 字舞流文

Subgroup analyses of METEOR, a randomized phase 3 trial of cabozantinib versus everolimus in patients (pts) with advanced renal cell carcinoma (RCC).

R. Motzer | T. Powles | T. Choueiri | N. Agarwal | C. Sternberg | B. Melichar | B. Rini | I. Davis | V. Grünwald | C. Szczylik | B. Escudier | P. Salman | D. Heng | F. Donskov | P. Wolter | N. Tannir | Thomas E. Hutson | M. Mangeshkar | A. Arroyo | D. Nosov